Table 3.

Most significantly associated polygenic risk scores with eGFR post-transplant

D/R	pT	eGFR	Estimate	SE	Pun	Padj	I2	N	N SNPs
combined	0.0001	1year	0.011	0.003	4.35×10−5	0.001	0.0%	3234	6229
recipient	0.0001	1year	0.008	0.002	8.68×10−5	0.005	6.2%	5295	6229
donor	0.0001	1year	0.006	0.003	0.01	0.755	2.7%	3564	6229
donor	0.1	5year	0.011	0.005	0.05	1	35.0%	2152	287016
recipient	0.0001	5year	0.008	0.004	0.06	1	0.0%	2494	6229
combined	0.0001	5year	0.008	0.005	0.11	1	0.0%	1930	6229
recipient	0.0001	∆	0.668	0.367	0.07	1	0.0%	2191	6229
donor	0.001	∆	-0.348	0.358	0.33	1	0.0%	1904	14097
combined	0.001	∆	-0.513	0.413	0.21	1	0.0%	1722	14097

Meta-analysis results for linear regression of polygenic risk scores vs. eGFR measures. 1/5 year = log₁₀ eGFR at 1/5 year post-transplant. ∆ = change in eGFR between 1 and 5 years post-transplant. Model was adjusted for all available significant clinical covariates and the first eight principal components at each site (see section 2.5 and 3.1). D/R = indicates whether the test was carried out on the recipient, donor or combined donor-recipient genotype. pT = p-value threshold of the calculated polygenic risk score. Estimate = estimated effect size. SE = standard error of the estimate. Pun = uncorrected p-value. Padj=approximate adjusted p-value. I² = the proportion of total variation in study estimates that is due to heterogeneity. N = number of individuals tested. N SNPs = number of SNPs at the given p-value threshold (prior to pruning for linkage disequilibrium).